8-K: Integer Holdings Reports Strong Q2 2025 Results, Raises Full-Year Profit Outlook

Integer Holdings Corporation announced robust second-quarter 2025 financial results, featuring double-digit sales and profit growth, leading to an upward revision of its full-year adjusted operating income and EPS outlook.

Summary

• Sales increased 11% to $476 million in the second quarter of 2025, with organic growth also at 11% compared to the second quarter of 2024.
• GAAP operating income rose 9% to $59 million, while non-GAAP adjusted operating income increased 15% to $81 million.
• GAAP income from continuing operations grew 19% to $37 million, and non-GAAP adjusted net income increased 23% to $55 million.
• GAAP diluted EPS from continuing operations increased 18% to $1.04, and non-GAAP adjusted EPS increased 19% to $1.55.
• Adjusted EBITDA increased 10% to $99 million.
• Total debt increased by $212 million from the end of 2024 to $1.202 billion, primarily to finance acquisitions and costs associated with the 2030 convertible note offering.
• Non-GAAP net total debt increased by $250 million to $1.204 billion, resulting in a leverage ratio of 3.2 times adjusted EBITDA as of June 27, 2025.
• Cardio & Vascular sales surged 24% in Q2 2025, driven by new product ramps in electrophysiology, Precision Coating and VSi Parylene acquisitions, and strong customer demand in neurovascular.
• Cardiac Rhythm Management & Neuromodulation sales increased 2% in Q2 2025, primarily due to strong growth in emerging neuromodulation customers with PMA products and normalized cardiac rhythm management growth, despite a planned decline from an early spinal cord stimulation customer.
• Other Markets sales decreased 38% in Q2 2025, mainly due to the planned multi-year portable medical exit announced in 2022.

Sentiment

Score: 8

Explanation: The company reported strong Q2 financial results with double-digit growth in sales and key profit metrics, and raised its full-year profit outlook. While debt increased due to acquisitions and convertible notes, and YTD GAAP income/EPS are down due to specific non-GAAP adjustments, the core operational performance and forward guidance are very positive.

Positives

• Strong overall sales growth of 11% in Q2 2025, with organic growth matching at 11%.
• Robust profit growth, with non-GAAP adjusted operating income up 15%, adjusted net income up 23%, and adjusted EPS up 19%.
• GAAP operating income increased 9% and GAAP income from continuing operations increased 19%.
• Management raised the 2025 full-year adjusted operating income outlook midpoint to 12% to 16% growth.
• Management raised the 2025 full-year adjusted EPS outlook midpoint to 18% to 23% growth.
• The Cardio & Vascular segment demonstrated exceptional growth with a 24% sales increase, driven by strategic initiatives and market demand.
• Growth in the Cardiac Rhythm Management & Neuromodulation segment (2.3% sales increase) was supported by emerging neuromodulation customers with pre-market approval products.

Negatives

• Total debt increased by $212 million from the end of 2024 to $1.202 billion, primarily due to financing acquisitions and convertible note offering costs.
• Non-GAAP net total debt increased by $250 million to $1.204 billion.
• Sales in the Other Markets segment decreased significantly by 38% due to the planned multi-year portable medical exit.
• GAAP income from continuing operations for the six months ended June 27, 2025, decreased 71.9% to $14.544 million compared to $51.798 million for the same period in 2024.
• GAAP diluted EPS from continuing operations for the six months ended June 27, 2025, decreased 72.1% to $0.41 compared to $1.47 for the same period in 2024.
• EBITDA for the six months ended June 27, 2025, decreased 18.2% to $119.274 million compared to $145.879 million for the same period in 2024.

Risks

• Dependence upon a limited number of customers.
• Pricing pressures and contractual pricing restraints from customers.
• Reliance on third-party suppliers for raw materials, key products, and subcomponents.
• Interruptions in manufacturing operations.
• Uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally.
• Ability to attract, train, and retain a sufficient number of qualified associates.
• Potential for harm to reputation and competitive advantage caused by quality problems related to products.
• Dependence upon information technology systems and ability to prevent cyber-attacks and other failures.
• Global climate change and the emphasis on Environmental, Social, and Governance matters by various stakeholders.
• Dependence upon senior management team and key technical personnel.
• Consolidation in the healthcare industry resulting in greater competition.
• Intense competition and ability to successfully market products.
• Ability to respond to changes in technology.
• Ability to develop new products and expand into new geographic and product markets.
• Ability to successfully identify, make, and integrate acquisitions.
• Ability to accurately forecast future performance based on operating results that often fluctuate.
• Significant amount of outstanding indebtedness and ability to remain in compliance with financial and other covenants under the credit agreement.
• Economic and credit market uncertainties that could interrupt access to capital markets, borrowings, or financial transactions.
• Conditional conversion features of Convertible Notes adversely impacting liquidity.
• Conversion of Convertible Notes diluting ownership interests of existing holders of common stock.
• Counterparty risk associated with capped call transactions.
• Financial and market risks related to international sales and operations.
• Complex international tax profile.
• Ability to realize the full value of intangible assets.
• Regulatory issues resulting from product complaints, recalls, or regulatory audits.
• Potential of becoming subject to product liability or intellectual property claims.
• Ability to protect intellectual property and proprietary rights.
• Ability to comply with customer-driven policies and third-party standards or certification requirements.
• Ability to obtain and/or retain necessary licenses from third parties for new technologies.
• Ability and the cost to comply with environmental regulations.
• Legal and regulatory risks from international operations.
• The healthcare industry is highly regulated and subject to various regulatory changes.
• Business being indirectly subject to healthcare industry cost containment measures that could result in reduced sales of products.

Future Outlook

Integer Holdings Corporation is raising its 2025 profit outlook midpoint, now expecting adjusted operating income growth of 12% to 16% and adjusted EPS growth of 18% to 23%. The company anticipates full-year 2025 sales between $1,850 million and $1,876 million, representing 8% to 9% growth, and cash flow from operating activities between $235 million and $255 million, representing 15% to 24% growth.

Management Comments

• Integer delivered another strong quarter of growth with sales up 11%, adjusted operating income up 15%, and adjusted EPS growth of 19% as we continue to execute our strategy.
• We are raising our 2025 profit outlook midpoint. We now expect adjusted operating income growth of 12% to 16% and adjusted EPS growth of 18% to 23%.

Industry Context

Integer Holdings Corporation operates as a leading medical device contract development and manufacturing organization (CDMO). The strong growth in Cardio & Vascular sales, driven by new product ramps and acquisitions, aligns with the ongoing innovation and demand in the broader medical device sector, particularly in high-growth areas like electrophysiology and neurovascular. The growth in emerging neuromodulation customers also reflects the expanding applications and market for advanced medical implants. The planned exit from the portable medical market indicates a strategic focus on core, higher-growth medical device segments.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry comparison.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, and raised full-year outlook, potentially leading to increased share value. However, dilution risk from convertible notes is mentioned.
• Employees: Continued growth and strategic focus may indicate job stability and potential for growth, especially in high-demand areas like electrophysiology and neurovascular.
• Customers: Continued innovation, new product ramps, and strategic acquisitions (Precision Coating, VSi Parylene) suggest enhanced capabilities and product offerings.
• Creditors: Increased debt levels, but the company's strong cash flow outlook and profitability growth suggest ability to manage debt. Leverage ratio of 3.2x is noted.

Next Steps

• Host a conference call on Thursday, July 24, 2025, at 8 a.m. CT / 9 a.m. ET to discuss these results.
• Make an updated Earnings Conference Call slide presentation available on the Company's website under Investor Relations News & Events.

Key Dates

Recommendation

The company delivered robust second-quarter results, exceeding expectations with significant sales and profit growth. The decision to raise the full-year adjusted operating income and EPS outlook signals strong management confidence and positive momentum. While debt has increased due to strategic acquisitions, these are expected to drive future growth, particularly in high-growth medical device segments like Cardio & Vascular and Neuromodulation. The planned exit from the portable medical market is a strategic move to focus on higher-margin core businesses. The strong operational performance and optimistic guidance make this an attractive investment opportunity.

Keywords

Medical Device, CDMO, Contract Manufacturing, Cardiac Rhythm Management, Neuromodulation, Cardio & Vascular, Electrophysiology, Neurovascular, Precision Coating, VSi Parylene, Earnings, Financial Results, Outlook, SEC Filing, 8-K, ITGR